SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : sciclone pharmaceuticals
SCLN 11.150.0%Oct 20 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JEB who wrote (866)8/19/2001 8:19:24 PM
From: Oak Tree  Read Replies (1) of 1137
 
There are a lot of companies developing their own ant-EGFR drug. Needless to say, this drug is not aimed at killing cancer cells. They, at best, simply hope it will grow slower. They also hope it will make the chemo work a bit better.

Chemotherapy is not judged successful if it doesn't shrink cancer. They are not even expecting this to shrink cancer. vis - this drug (these drugs) are less good than chemotherapy.

Its hard to understand all the hype around these drugs. Patience should yield a nice profit to the careful shorter of IMCL.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News